Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists

Medical Care

Volumn 52, Issue 7, 2014, Pages 579-585

  Kim, Simon P ^a   Gross, Cary P ^b   Nguyen, Paul L ^c   Smaldone, Marc C ^d   Shah, Nilay D ^e   Karnes, R Jeffrey ^e   Thompson, R Houston ^e   Han, Leona C ^e   Yu, James B ^b   Trinh, Quoc D ^c   Ziegenfuss, Jeanette Y ^f   Sun, Maxine ^g   Tilburt, Jon C ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^e MAYO CLINIC   (United States)

^f HEALTHPARTNERS INSTITUTE   (United States)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

active surveillance; outcomes; prostate cancer; recommendations; survey

Indexed keywords

ADULT; ARTICLE; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER THERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION ONCOLOGIST; UROLOGIST;

ADULT; ATTITUDE OF HEALTH PERSONNEL; BRACHYTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RISK FACTORS; UNITED STATES; UROLOGY; WATCHFUL WAITING;

EID: 84902457533     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000155     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63: 11-30.
2. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101: 1325-1329.
3. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148: 435-448.
4. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28: 126-131.
5. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
6. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
7. Role of active surveillance in the management of men with localized prostate cancer. 2011. Available at: http://consensus.nih.gov/2011/ prostategetinvolved.htm. Accessed February 1, 2013.
8. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28: 1117-1123.
9. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 pt 2):S14-S19. (Pubitemid 47224952)
10. van den Bergh RC, Albertsen PC, Bangma CH, et al. Timing of curative treatment for prostate cancer: a systematic review. Eur Urol. 2013;64: 204-215.
11. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62: 976-983.
12. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117: 2058-2066.
13. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309: 2587-2595.
14. Davison BJ, Oliffe JL, Pickles T, et al. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum. 2009;36: 89-96.
15. Aizer AA, Paly JJ, Zietman AL, et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012;30: 3071-3076.
16. Bul M, Zhu X, Rannikko A, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. 2012;62: 195-200.
17. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63: 597-603.
18. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100: 1144-1154.
19. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364: 1708-1717.
20. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352: 1977-1984.
21. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367: 203-213.
22. Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158: 709-717.
23. Raldow AC, Presley CJ, Yu JB, et al. The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med. 2012;172: 362-363.
24. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171: 1393-1401.
25. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 pt 2):S21-S25; discussion S26-27.
26. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22: 2141-2149.
27. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283: 3217-3222.
28. Carter HB. Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr. 2012;2012: 175-183.
29. Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr. 2012;2012: 146-151.
30. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50: 1129-1136.
31. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res. 2001;35: 1347-1355.
32. Jang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010;170: 440-450.
33. Lin GA, Aaronson DS, Knight SJ, et al. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59: 379-390.
34. O'Brien MA, Whelan TJ, Villasis-Keever M, et al. Are cancer-related decision aids effective? A systematic review and meta-analysis. J Clin Oncol. 2009;27: 974-985.
35. Fowler FJ Jr, Gallagher PM, Bynum JP, et al. Decision-making process reported by Medicare patients who had coronary artery stenting or surgery for prostate cancer. J Gen Intern Med. 2012;27: 911-916.
36. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29: 1335-1341.
37. Kim SP, Karnes RJ, Nguyen PL, et al. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013;189: 2092-2098.